Navigation Links
Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
Date:10/28/2009

Intermezzo® or placebo. In the first study, a sleep laboratory trial using an objective polysomnographic endpoint, Intermezzo® demonstrated a statistically significant decrease versus placebo in the time it took patients to return to sleep as measured by Latency to Persistent Sleep. In the second study, an outpatient trial, Intermezzo® demonstrated a statistically significant decrease in Latency to Sleep Onset, a subjective patient reported endpoint. The most common adverse event seen in these trials was headache (2.7 percent active versus 1.4 percent placebo in the outpatient study).

Transcept is actively pursuing patents to protect Intermezzo® in the United States and key non-U.S. markets, and, as part of the NDA submission, has requested that the FDA grant three years of Hatch-Waxman marketing exclusivity to Intermezzo®.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), which is currently being reviewed by the U.S. Food and Drug Administration (FDA) as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.

Forward Looking Statements

This press release contains forward looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Transcept disclaims any intent or obligation to update t
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Transcept Pharmaceuticals to Report First Quarter 2009 Results
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
5. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
6. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
7. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
8. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
9. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
10. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
11. BioMarin Acquires Huxley Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today announced that Robert A. Ingram has ... is an ardent champion for innovation in the lifesciences industry, ... on Edwards, board as we pursue our focused innovation strategy," ... "Bob has provided a valuable perspective to our board, drawing ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation (NASDAQ: ... its second quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, August 6, ... and other business developments. Interested parties may ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... and CAMBRIDGE, Mass., Dec. 11 ,Amylin Pharmaceuticals, Inc., ... Company (NYSE:, LLY ) and Alkermes, Inc. ... the U.S. Food and,Drug Administration (FDA) recently indicated ... appropriate to use as the basis for demonstrating,comparability ...
... Bart Classen published this week in Diabetes & Metabolic ... epidemics of type 2 diabetes/obesity/metabolic syndrome, like type 1 diabetes, ... causing an epidemic of type 1 diabetes in children. ... as well as Classen,s recently published data demonstrate that the ...
Cached Medicine Technology:Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 2Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 3Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 4Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 5Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 6Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 7Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization 2
(Date:7/31/2015)... Tenn. (PRWEB) , ... July 31, 2015 , ... The ... Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight ... focused on cancer research between Methodist Healthcare, The West Clinic and The University of ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to enjoy ... comes time to cook the next meal, making July the most appropriate to be ... grilling tips and recipes. , Make the next cookout different than the ones in ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... Rally Insurance Group, Inc. has re-branded their social media profiles to better connect ... way for consumers to communicate, find information, share insights and opinions. The Rally ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source ... launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and ... Prep from MDLinx makes preparing for the exam easy and painless. MDLinx offers ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According to the article ... floor of the Pasadena courthouse was contained and extinguished by the city’s fire department before ... in the building at the time of the fire, and it was a fire alarm ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... , NEW YORK, July 14 Today JBFCS ( ... time fundraising event -- the Hudson Valley Bike Ride. The human services ... more than $280,000. The objective has now been increased to $300,000. ... of the bike ride and President-Elect of JBFCS, "We are thrilled by the ...
... , , NEW YORK, July 14 ... it will release financial results for the second quarter ended June 30, ... In addition, Eamonn Hobbs, the Company,s new President & ... on Monday, July 27, 2009 at 4:30 p.m. Eastern / 1:30 ...
... , , , ... STAA ) today announced that it will release financial results for the ... before the market opens. In addition, ... of July 3, 2009 were $13.1 million. This balance includes the proceeds ...
... , DEERFIELD BEACH, Fla., July 14 A ... suggests drinking fat-free milk in the morning may be better than drinking ... However, the study only looks at feeling full, not weight loss ... are intolerant to proteins in milk, or lactose intolerant, which can cause ...
... , , ... serve as its healthcare vertical leader. Silva-Craig will be responsible for ... healthcare market overall. He will report directly to Jeff Hellinga, president ... With more than a decade of experience in public and ...
... ... Advances in fractional laser technology have resulted in the Fractional Eyelift, a laser light-based procedure ... the Juva Skin & Laser Center pioneered the procedure. , ... (PRWEB) July 14, 2009 -- For many, anxiety over cosmetic ...
Cached Medicine News:Health News:JBFCS Surpasses Fundraising Goal For Hudson Valley Bike Ride Despite Difficult Financial Times 2Health News:Delcath Systems to Host July 27th Conference Call to Update Investors on Recent Progress 2Health News:STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call 2Health News:Milk: Does It Do A Body Good? 2Health News:Milk: Does It Do A Body Good? 3Health News:TransUnion Expands Healthcare Vertical With New Hire, Milton Silva-Craig 2Health News:Fractional Eyelift Procedure Reduces Eyelid Drooping and Wrinkles with Minimal Recovery Time 2Health News:Fractional Eyelift Procedure Reduces Eyelid Drooping and Wrinkles with Minimal Recovery Time 3
... imaging agent that is labeled with technetium ... and localization of regions of reversible myocardial ... infarction under exercise and rest conditions. Imaging ... or up to 4 hours after administration ...
Universal Hub with Varying Blade Edge Diameters For Mounting the Blade to the Handle; Stainless Steel....
... Chloride Tl 201 Injection is supplied in ... diagnostic radiopharmaceutical for intravenous administration. Each milliliter ... Tl 201 at calibration time, made isotonic ... with 0.9% (v/v) benzyl alcohol. The pH ...
Elongated Loop, Slightly Curved; in Stainless Steel....
Medicine Products: